UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Date of Report: June 30, 2020
Commission File Number: 001-36891
Cellectis S.A.
(Exact Name of registrant as specified in its charter)
8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
General Meeting
Cellectis S.A. (the “Company”) held its Combined Ordinary and Extraordinary General Meeting (the “Meeting”) on June 29, 2020. Filed as Exhibits 99.1 and 99.2 hereto are the press release and the voting results for the Meeting, respectively.
EXHIBIT INDEX
| Exhibit |
Title | |
| 99.1 | Press Release, dated June 29, 2020. | |
| 99.2 | Voting Results for the Combined Ordinary and Extraordinary General Meeting. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CELLECTIS S.A. (Registrant) | ||||||
| June 30, 2020 | By: | /s/ André Choulika | ||||
| André Choulika | ||||||
| Chief Executive Officer | ||||||
Exhibit 99.1
PRESS RELEASE
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 29, 2020
June 29, 2020 – New York – Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) was held on June 29, 2020 at its head office in Paris, France.
At the meeting, during which more than 63% of voting rights were exercised, Resolutions 1 through 22, and Resolutions 26 through 28 were adopted. Resolutions 23, 24, 25 and 29 were rejected. The detailed results of the vote and the resolutions are available on the company’s website: https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
TALEN® is a registered trademark owned by Cellectis.
For further information, please contact:
Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com
IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com
###
Exhibit 99.2
CELLECTIS - GENERAL ASSEMBLY - 06/29/2020
VOTE RESULTS
Ordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold |
Total votes | Shares represented by the votes cast |
Percentage of the
|
Out of vote voting rights |
Null voting rights |
Quorum | |||||||||||||||||
|
Votes |
% | Votes | % | Votes | % | |||||||||||||||||||||||
| 1 |
Approval of the financial statements for the financial year ended December 31, 2019.
| |||||||||||||||||||||||||||
| 1 |
Carried |
32 296 425 | 99,93 % | 24 127 | 0,07 % | 26 074 | - | 32 320 552 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 2 |
Approval of the consolidated financial statements for the financial year ended December 31, 2019.
| |||||||||||||||||||||||||||
| 2 |
Carried |
32 297 425 | 99,93 % | 24 127 | 0,07 % | 25 074 | - | 32 321 552 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 3 |
Allocation of income for the financial year ended December 31, 2019.
| |||||||||||||||||||||||||||
| 3 |
Carried |
32 313 406 | 99,91 % | 27 654 | 0,09 % | 5 566 | - | 32 341 060 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 4 |
Approval of the agreements referred to in articles L. 225-38 and the following sections of the French commercial code.
| |||||||||||||||||||||||||||
| 4 |
Carried |
25 155 570 | 77,79 % | 7 181 381 | 22,21 % | 9 675 | - | 32 336 951 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 5 |
Setting the amount of the total compensation (directors fees) to be granted to the non-executive directors.
| |||||||||||||||||||||||||||
| 5 |
Carried |
32 228 592 | 99,69 % | 101 331 | 0,31 % | 16 703 | - | 32 329 923 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 6 |
Renewal of the mandate of a member of the Board of Directors of Mrs. Annick Schwebig.
| |||||||||||||||||||||||||||
| 6 |
Carried |
27 709 202 | 85,68 % | 4 631 465 | 14,32 % | 5 959 | - | 32 340 667 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
CELLECTIS - GENERAL ASSEMBLY - 06/29/2020
VOTE RESULTS
Ordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold |
Total votes | Shares represented by the votes cast |
Percentage of the
|
Out of vote voting rights |
Null voting rights |
Quorum | |||||||||||||||||
|
Votes |
% | Votes | % | Votes | % | |||||||||||||||||||||||
| 7 |
Renewal of the mandate of a member of the Board of Directors of Mr. Laurent Arthaud.
| |||||||||||||||||||||||||||
| 7 | Carried | 28 206 474 | 87,22 % | 4 132 979 | 12,78 % | 7 173 | - | 32 339 453 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 8 |
Renewal of the mandate of a member of the Board of Directors of Mr. Pierre Bastid.
| |||||||||||||||||||||||||||
| 8 | Carried | 27 987 046 | 86,54 % | 4 352 407 | 13,46 % | 7 173 | - | 32 339 453 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 9 |
Renewal of the mandate of a member of the Board of Directors of Mr. Rainer Boehm.
| |||||||||||||||||||||||||||
| 9 | Carried | 28 504 457 | 88,14 % | 3 834 986 | 11,86 % | 7 183 | - | 32 339 443 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 10 |
Renewal of the mandate of a member of the Board of Directors of Mr. Hervé Hoppenot.
| |||||||||||||||||||||||||||
| 10 | Carried | 27 920 532 | 86,34 % | 4 419 029 | 13,66 % | 7 065 | - | 32 339 561 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 11 |
Authorization to be given to the board of directors to buy back Company shares.
| |||||||||||||||||||||||||||
| 11 | Carried | 29 519 026 | 91,30 % | 2 814 240 | 8,70 % | 13 360 | - | 32 333 266 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
CELLECTIS - GENERAL ASSEMBLY - 06/29/2020
VOTE RESULTS
Extraordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold |
Total votes | Shares represented by the votes cast |
Percentage of the
|
Out of vote voting rights |
Null voting rights |
Quorum | |||||||||||||||||
|
Votes |
% | Votes | % | Votes | % | |||||||||||||||||||||||
| 12 |
Authorization to be given to the board of directors for the purpose of reducing the share capital through the cancellation of shares in the context of the authorization to buy back its own shares.
| |||||||||||||||||||||||||||
| 12 |
Carried |
32 220 812 | 99,71 % | 93 329 | 0,29 % | 32 485 | - | 32 314 141 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 13 |
Delegation of authority to be granted to the board of directors for the purpose of increasing the share capital by issuing ordinary shares and /or any securities, with a waiver of the preferential subscription rights of the shareholders, in favor of categories of persons meeting specified characteristics.
| |||||||||||||||||||||||||||
| 13 |
Carried |
21 646 301 | 66,99 % | 10 667 880 | 33,01 % | 32 445 | - | 32 314 181 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 14 |
Delegation of authority to be granted to the board of directors for the purpose of increasing the share capital by issuing ordinary shares and /or any securities, with a waiver of the preferential subscription rights of the shareholders, in favor of a first category of persons meeting specified characteristics.
| |||||||||||||||||||||||||||
| 14 |
Carried |
21 643 493 | 66,98 % | 10 669 855 | 33,02 % | 33 278 | - | 32 313 348 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 15 |
Delegation of authority to be granted to the board of directors for the purpose of increasing the share capital by issuing ordinary shares and /or any securities, with a waiver of the preferential subscription rights of the shareholders, in favor of a second category of persons meeting specified characteristics.
| |||||||||||||||||||||||||||
| 15 |
Carried |
21 643 623 | 66,98 % | 10 669 235 | 33,02 % | 33 768 | - | 32 312 858 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 16 |
Delegation of authority to be granted to the board of directors for the purpose of increasing the share capital through the issuance of ordinary shares or of any securities with a waiver of the preferential subscription rights, in favor of a category of persons taking part to a line equity financing or bond financing.
| |||||||||||||||||||||||||||
| 16 |
Carried |
21 644 220 | 66,98 % | 10 668 638 | 33,02 % | 33 768 | - | 32 312 858 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 17 |
Delegation of authority to be granted to the board of directors for the purpose of increasing the share capital immediately or in the future by issuing ordinary shares or any securities, while maintaining the preferential subscription rights of shareholders.
| |||||||||||||||||||||||||||
| 17 |
Carried |
25 221 209 | 78,05 % | 7 091 761 | 21,95 % | 33 656 | - | 32 312 970 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
CELLECTIS - GENERAL ASSEMBLY - 06/29/2020
VOTE RESULTS
Extraordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold |
Total votes | Shares represented by the votes cast |
Percentage of the
|
Out of vote voting rights |
Null voting rights |
Quorum | |||||||||||||||||
|
Votes |
% | Votes | % | Votes | % | |||||||||||||||||||||||
| 18 |
Delegation of authority to be granted to the board of directors for the purpose of increasing the share capital through the issuance of ordinary shares and /or any securities, with waiver of the preferential subscription rights of the shareholders, through a public offering.
| |||||||||||||||||||||||||||
| 18 |
Carried |
21 642 870 | 66,98 % | 10 670 821 | 33,02 % | 32 935 | - | 32 313 691 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 19 |
Delegation of authority to be granted to the board of directors for the purpose of increasing the share capital through the issuance of ordinary shares and /or of any securities, with waiver of the preferential subscription rights of the shareholders, through an offer referred to in Article L. 411-2 of the French monetary and financial code.
| |||||||||||||||||||||||||||
| 19 |
Carried |
21 664 489 | 67,04 % | 10 649 202 | 32,96 % | 32 935 | - | 32 313 691 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 20 |
Delegation granted to the board of directors to increase the number of securities to be issued in case of share capital increase with or without preferential subscription rights.
| |||||||||||||||||||||||||||
| 20 |
Carried |
21 772 204 | 67,38 % | 10 541 422 | 32,62 % | 33 000 | - | 32 313 626 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 21 |
Overall limitations to the amount of issuances made under the 13th to 15th resolutions, the 16th resolution, the 17th resolution, 18th resolution, the 19th resolution and the 20th resolution above.
| |||||||||||||||||||||||||||
| 21 |
Carried |
27 949 605 | 86,49 % | 4 365 566 | 13,51 % | 31 455 | - | 32 315 171 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 22 |
Delegation of authority to be granted to the board of directors for the purpose of increasing the share capital by incorporation of premiums, reserves, profits or others.
| |||||||||||||||||||||||||||
| 22 |
Carried |
32 271 499 | 99,87 % | 41 792 | 0,13 % | 33 335 | - | 32 313 291 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 23 |
Authorization to be given to the board of directors to grant options to subscribe or purchase Company’s shares.
| |||||||||||||||||||||||||||
| 23 |
Rejected |
17 582 188 | 54,40 % | 14 737 830 | 45,60 % | 26 608 | - | 32 320 018 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
CELLECTIS - GENERAL ASSEMBLY - 06/29/2020
VOTE RESULTS
Extraordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold |
Total votes | Shares represented by the votes cast |
Percentage of the
|
Out of vote voting rights |
Null voting rights |
Quorum | |||||||||||||||||
|
Votes |
% | Votes | % | Votes | % | |||||||||||||||||||||||
| 24 |
Authorization be given to the board of directors for the allocation of free shares existing and/or to be issued in the future.
| |||||||||||||||||||||||||||
| 24 |
Rejected |
17 748 878 | 54,93 % | 14 563 783 | 45,07 % | 33 965 | - | 32 312 661 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 25 |
Delegation of authority to be granted to the board of directors to issue warrants giving the right to subscribe ordinary shares of the Company - Cancellation of the preferential right of subscription to the benefit of a category of persons meeting specific characteristics.
| |||||||||||||||||||||||||||
| 25 |
Rejected |
17 788 564 | 55,05 % | 14 524 427 | 44,95 % | 33 635 | - | 32 312 991 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 26 |
Overall limitations to the amount of issues made under the 23rd resolution, 24st resolution and the 25th resolution above.
| |||||||||||||||||||||||||||
| 26 |
Carried |
28 057 540 | 86,82 % | 4 257 823 | 13,18 % | 31 263 | - | 32 315 363 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 27 |
Amendment of article 12 of the articles of association “meeting of the board of directors” in order to provide for the possibility for the board of directors to take certain decisions by means of written consultation.
| |||||||||||||||||||||||||||
| 27 |
Carried |
32 275 062 | 99,88 % | 37 412 | 0,12 % | 34 152 | - | 32 312 474 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 28 |
Amendment of Article 18 of the Articles of Association “General Meetings - quorum - voting - number of votes” in order to update the legal provisions concerning the procedures for determining the majority required for the adoption of resolutions by general meetings of shareholders.
| |||||||||||||||||||||||||||
| 28 |
Carried |
32 274 711 | 99,89 % | 36 987 | 0,11 % | 34 928 | - | 32 311 698 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||
| 29 |
Delegation to be granted to the board of directors for the purpose of an increase in the share capital whose subscription would be reserved to members of a company savings plan established pursuant to articles L. 3332-1 and following of the French labor code.
| |||||||||||||||||||||||||||
| 29 |
Rejected |
16 986 839 | 52,58 % | 15 317 068 | 47,42 % | 42 719 | - | 32 303 907 | 27 106 620 | 63,801 % | 0 | 0 | 63,801 % | |||||||||||||||